AKE.PA (Arkema SA) — Execution Log #

Status as of 2026-05-18: T1 EXECUTED. Limit order filled at the opening auction. See "Actual Fill" section below for transaction details.

Position Summary (actual) #

Pre-Buy Red Flag Check (2026-05-16) #

Full red flag check run on 2026-05-16, one day after thesis was written. No material change in 24-72 hours. Verdict: GO.

GREEN (thesis intact) #

• Price action: EUR 62.65, flat to thesis. Intraday range orderly. 5-day fade from EUR 65.20 (May 11 spike) is normal low-beta chemical name behavior.
• Dividend: EUR 3.60/share confirmed for May 27 payment, EUR 272M total payout vs LTM EBITDA EUR 943M = 29% payout ratio, well-covered.
• Balance sheet: Net debt EUR 2.0B, net debt/LTM EBITDA 2.13x, deleveraging from EUR 2.16B prior year. No covenant pressure.
• Earnings calendar: clean window until late July Q2 results.

AMBER (watch closely, but not blocking) #

• Q1 guidance language: Q2 EBITDA "comparable to Q2 2025" (~EUR 276M) — flat, not accelerating. Acrylic upside is forward promise, not yet booked.
• Analyst dispersion widened post-Q1: Berenberg downgraded April 20 to Hold at EUR 62 (exactly current price); Barclays lowest at EUR 47; JPM cut to EUR 55. Consensus mean EUR 63.88. The most thesis-aware bear (Berenberg) puts us at fair value, not overvalued.
• Short interest data unavailable for Paris listing (standard data gap, not a flag).

RED (pre-existing, documented in thesis — not blocking) #

• No insider buying since 2024. Only transaction in trailing 12 months: deputy GM sale of 7,602 shares at EUR 52 (Nov 2025) — small, pre-inflection, not from CEO/CFO/board. Per shr-002, absence of buying is missing-confirming-signal, not contrary signal.
• Hormuz normalization risk: real and near-term (6-12 months). The ~EUR 100M EBITDA windfall from acrylic spreads at $900/t will fade as Gulf supply returns. Berenberg's bear thesis is this exact risk. Mitigated by: thesis built on normalized spreads, not the windfall; other 3 pillars (cyclical recovery, battery materials, asset floor) carry the case.

Entry Rationale #

Arkema is the textbook inflection-point value setup the four-pillar thesis is designed for. The market is pricing the stock as if the chemicals cycle won't recover (P/B 0.77x = 23% discount to book, 5.67% dividend yield, fwd P/E 10.5x). Q1 2026 EBITDA snapped from a EUR 74M trough to EUR 283M, the first inflection signal. Even strip out 100% of the temporary Hormuz acrylic windfall, sequential improvement is real across Bostik (adhesives), Coatings, and Advanced Materials.

The 3-year EV is +40c/EUR (conservative weighting, consistent with the recent portfolio retrospective showing ex-SLS picks have lagged VWCE). Bull case +75%, base +28%, bear ~0% — and the bear case still pays ~17% of dividends. Two layers of downside cushion (assets + income) protect against being wrong on cyclical timing.

Why now and not wait: EUR 36 dividend ex May 25. Missing the ex-date means waiting 12 months. The technical setup also says we're at the upper bound of the recent recovery move — there's some "buying near a target" risk, but the fundamental thesis is multi-year, not 8-week. The dividend capture is real money; technical target risk is theoretical.

Why full T1 and not split: With only EUR 660 in the value bucket, splitting into 5 + 5 cuts the dividend in half (EUR 18 instead of EUR 36) and leaves cash sitting idle. The structural T2 funding comes from monthly contributions, not from holding back T1 capital. See "Tranche 2 Plan" below.

Graham screen score 4/7 (Growth Stock Addendum applies per shr-004). Forward P/E 10.5x easily passes the implied-growth test.

Tranche 2 Plan — KILL conditions, not GO conditions #

Lesson from RI.PA T2 paralysis (still pending after 10 months, partly due to BF.B M&A interruption per shr-036, partly due to fuzzy GO conditions that never fully aligned): T2 triggers should default to BUY on price weakness UNLESS the thesis is structurally broken. This flips the framework from "wait for positive confirmation" to "act unless negative evidence has arrived" — boolean, fast to verify, no paralysis.

Trigger #

If AKE.PA closes at or below EUR 52 on any day, deploy that month's contribution (EUR 200-300) into AKE — UNLESS any of these kill conditions has happened:

Boolean check workflow at trigger: open quarterly report → scan for each line item → 30 seconds per condition → if all 5 = "no," buy. Don't wait for analyst upgrades. Don't wait for Hormuz news to be "clear." Don't wait for the chart to look good. The drop IS the buy signal.

Why EUR 52 (not 50) #

• Cohen de Lara (Next Momentum, 2025-11) had EUR 53.40 as technical invalidation — slightly above
• Thesis bear case is EUR 50-55 — EUR 52 sits in the middle
• Going for EUR 50 would optimize for the exact bottom — increases probability of not firing at all
• Per shr-016: price drops on unchanged fundamentals are buy signals, not exit signals

Sizing #

• T2 funded from monthly contribution, not pre-reserved cash
• If contribution is EUR 200 at EUR 52 → ~4 shares add
• If contribution is EUR 300 at EUR 48 → ~6 shares add
• Total position after T2: 14-16 shares, EUR 700-1,000 cost basis depending on T2 fill price

Behavioral pre-commitment #

• Watchlist alert AKE.PA-T2 set at EUR 52 — fires via ntfy
• Calendar reminder for Q2 results (late July) — that's the proactive kill-condition check
• This document is the pre-commitment. Read it before deciding NOT to buy at EUR 52.

Exit Plan #

Profit targets (sell in thirds — per shr-016) #

Watchlist alerts: AKE.PA-TP1, TP2, TP3 all active.

Fundamental stops (no price-based stop losses — shr-016, shr-024) #

• EXIT: net debt/EBITDA > 5x, dividend cut sustained > 2 quarters
• RE-SCORE within 5 trading days: Le Hénaff departure, Bostik impairment > EUR 500M, two consecutive quarterly misses, qualitative score < 3/5
• TRIM half position: net debt/EBITDA > 3x, PFAS judgment > EUR 200M

Time horizon #

• Base case: 3-5 years (cyclical recovery + battery materials ramp)
• Stretch: 10+ years if value-compounder thesis develops — per user 5x objective, AKE.PA could plausibly compound to EUR 300+ over a decade at 12-14% CAGR, BUT requires reinvested dividends and patience through cycles
• Re-score: every quarterly result + on any material Hormuz status change
• Hard exit if no progress by: October 2028 (~30 months) — re-evaluate if still trading below EUR 70

Related Documents #

• Investment thesis: output/pipeline/reports/AKE_PA_inflection_thesis_2026-05-15.md — four-pillar narrative with scenarios, EV calc, SWOT
• Hormuz explainer: output/research/stocks/AKE_PA/hormuz_risk_explained_2026-05-16.md — plain-language explanation of why a strait between Iran and Oman shows up in Arkema's earnings
• Pipeline cycle reports: output/pipeline/reports/pipeline-2026-05-05.md (Stage 2 ranking), output/pipeline/reports/phase2-deep-dive-2026-05-05.md
• Red flag check (2026-05-16): in this document (Pre-Buy Red Flag Check section)
• Plan JSON: output/graham/scores/AKE_PA_plan.json

Watchlist Alerts Active #

Verify with uv run pm watch list | grep AKE.PA.

Actual Fill (DEGIRO confirmation) #

Source: /var/lib/pelayar-fail/storage/DEGIRO - Transaktionsbestätigung- Kauf 10 Arkema SA @ 62,25.pdf

Fill quality: filled in the opening auction (09:00:18) at EUR 0.75 below limit and EUR 0.40 below thesis price. No slippage, no chasing. Dividend ex-date is 7 calendar days out — EUR 36 captured.

Post-Execution Checklist #

• [x] Replace "planned" with actual fill price, shares, total cost (2026-05-18)
• [x] Update MEMORY.md Active Graham Portfolio block with AKE.PA position (2026-05-18)
• [x] Update plan JSON tranche_1_price and tranche_1_date with actuals (2026-05-18)
• [ ] Commit changes: feat: AKE.PA T1 executed — 10 sh at EUR 62.25, total EUR 627.40
• [ ] Add calendar entry: Q2 2026 results late July (proactive kill-condition check)
• [ ] Verify dividend EUR 36 lands May 27 (post-fill confirmation)